Clinical trial
COLONYVAQ™-CRC, a Physics-aware, Quantum-Classical AI-Guided Personalized Neoantigen Peptide Vaccine, Administered in Combination With Standard Adjuvant Oxaliplatin-based Chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab 3 mg/kg in Patients With Completely Resected Stage III Microsatellite-stable (MSS)
NCT07328087 is registered in ClinicalTrials.gov with Biogenea Pharmaceuticals Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- COLONYVAQ™-CRC, a Physics-aware, Quantum-Classical AI-Guided Personalized Neoantigen Peptide Vaccine, Administered in Combination With Standard Adjuvant Oxaliplatin-based Chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab 3 mg/kg in Patients With Completely Resected Stage III Microsatellite-stable (MSS)
- Lead sponsor
- Biogenea Pharmaceuticals Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 2, 2026
- Completion date
- December 2, 2031
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer metastatic, colorectal cancer stage iii, colorectal cancer stage iv